Empagliflozin After Acute Myocardial Infarction | Nejm

Empagliflozin after Acute Myocardial Infarction | NEJM

Empagliflozin after acute myocardial infarction: Results of the EMPACT-MI Trial #ACC24

PCR

ESC 2022: The EMMY Trial: Empagliflozin in Patients with Acute MI | Prof Harald Sourji

Empagliflozin and heart failure

Cardiology Update

The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in STEMI - Weekly Research Conference

University of Ottawa Heart Institute

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute my... | RTCL.TV

AHA 2021: EMPATROPISM FE: Effects of Empagliflozin on Iron Metabolism in Non-diabetic HF Patients

Quick Take: Empagliflozin nach akutem Myokardinfarkt

Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V.

EMPULSE Trial. EMPAGLIFLOZIN in Acute Heart Failure. AHA2021

RECOVERY Trial - Empagliflozin

Oxford Population Health

SGLT-2 I after Myocardial Infarction - EMPACT-MI - Dr. Javed Butler (Jackson, MS, USA)

The EMPACT-MI Trial

The Canadian VIGOUR Centre

Empagliflozin in acute myocardial infarction

Teleducación Facultad de Medicina UdeA

EMPULSE: The ‘missing link’ for empagliflozin in heart failure | Adriaan Voors

Medicine Matters diabetes

Empagliflozin reduces CV death in patients with type 2 diabetes at high CV risk

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Medical Dialogues

Medication harm in patients after Acute Myocardial Infarction

NICE Guidelines on SGLT2 inhibitors

Cardiomyopathy UK

NUHCS - Acute Myocardial Infarction (AMI)

NUHCS: National University Heart Centre, Singapore

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time

Medical Dialogues